Jizhi Medical Completes Tens of Millions RMB Series A Financing to Advance Affordable Digital Rehabilitation Robotics

Recently, Beijing Litaike Technology Co., Ltd., the parent company of Hangzhou Jizhi Medical Technology Co., Ltd. (hereinafter referred to as “Jizhi Medical”), completed a Series A financing round worth tens of millions of yuan.This round of financing was jointly invested by China Xinxing Assets and Qiandao Group., the financing proceeds will be aligned with the company’s vision and mission to provide the industry with Available and Affordable digital rehabilitation robots and fitness products, thereby driving the scaled mass production, marketing deployment, and brand building of the company’s torque motor products.

Jizhi Medical, established in 2014, is a technology innovation company specializing in digital rehabilitation assessment and intelligent rehabilitation robotics. It was recognized as a National High-Tech Enterprise in 2019. The team’s core technological barriers are built upon 16 years of accumulated research in rehabilitation robotics and the interpretation of medical data from rehabilitation assessments. The company possesses independent intellectual property rights in flexible robot control technology, as well as brain cognition and neuropsychological auxiliary diagnostic technologies based on eye-tracking algorithms. As one of the few tech innovators in China deeply engaged in foundational rehabilitation algorithm technologies, Jizhi Medical has secured international invention patent protections in China, the United States, and Europe for multiple technologies. The company has currently obtained Class II medical device registration certificates for several products, with an annual output value reaching tens of millions of RMB. This round of financing will accelerate Jizhi Medical’s product layout and regulatory certification in the areas of quantitative rehabilitation assessment and intelligent sports health.

Since launching R&D on DDR direct-drive motor technology in 2019, the company has achieved fully independent R&D and industrialization of core components, including motors, controllers, and encoders. It has currently completed mass production of DDR direct-drive motors in various specifications. The first rehabilitation robot product based on its self-developed DDR direct-drive motor—the Knee Joint Isokinetic Strength Measurement and Trainer—has been launched and is now on the market. As a cost-effective professional isokinetic product currently available, it gained recognition from experts at dozens of medical institutions within just a few months of its launch. Breakthroughs in DDR direct-drive motor and control technology not only demonstrate Jizhi Medical’s technical depth in the field of robotic control but also provide greater possibilities for the company’s future strategic product layout, leading intelligent rehabilitation robots and digital fitness products into a truly intelligent and digital era.

Jizhi Medical has been dedicated to exploring and deeply cultivating the field of intelligent health, with the goal of providing users with products and services that offer greater cost-effectiveness and a superior experience. Guided by the underlying logic of product development derived from the intelligent and modern transformation of hospital rehabilitation departments, the company has completed its To-B product portfolio for hospitals. This portfolio includes eye-tracking cognitive rehabilitation systems, anti-spasticity manipulation robots, muscle tone testers, isokinetic strength testing and training systems, and naked-eye VR intelligent assessment and training systems, covering rehabilitation products related to neurological injuries, orthopedic injuries, and sports medicine. From quantitative rehabilitation assessment to personalized training prescriptions, we ensure efficient rehabilitation treatment for every patient while making the rehabilitation process more enjoyable.

As a country with a vast population, China faces an intensifying aging society, making the establishment of a three-tier rehabilitation medical system an urgent priority. Governments at all levels have devoted significant attention and resources to this endeavor. As a participant in this field, Hangzhou Jizhi Medical Technology Co., Ltd. (“Jizhi Medical”) has been striving diligently. In response to the transformation of primary healthcare institutions toward rehabilitation services, we have launched more accessible rehabilitation products to serve a broader patient population. Addressing the growing societal shift in mindset from “treatment” to “prevention,” we have strategically developed an intelligent consumer-oriented (To-C) health product line focused on physical function enhancement. Jizhi Medical remains committed to its mission of “establishing a moral compass for the world and securing the well-being of the people,” continuously advancing in the field of intelligent health to deliver due value and contributions to the initiatives of “Healthy China,” “Healthy Society,” and “Healthy People.”

Ren Yupeng, Founding Partner and Chairman of Jizhi Medicalstated: “We extend our sincere gratitude to the investors for their recognition and support of Jizhi Medical. This round of financing marks another milestone in Jizhi Medical’s rapid development journey. The successful completion of our Series A financing not only demonstrates the investors’ confidence in the innovation and industrialization capabilities of the Jizhi Medical team, but also reflects their strong belief in the highly differentiated product pipeline and commercial prospects of our future products in the fields of rehabilitation robotics and digital fitness. The Jizhi Medical team has remained true to its original aspiration and mission: ‘Where there is movement, there is Jizhi,’ striving to become a leader in intelligent health. We will further intensify our efforts in technological innovation and talent acquisition, accelerate the development and strategic layout of our product pipeline, and provide safer and more efficient digital assessment and rehabilitation training solutions for individuals with neurological injuries, orthopedic injuries, sports injuries, as well as those engaged in professional sports and fitness.”

ChinaMr. Song Qingliang, Guoxin Emerging Assets“Jizhi Medical is an innovative R&D enterprise with profound technological accumulation in rehabilitation robotics. Its founding team possesses deep insights into and a thorough understanding of industry trends and clinical needs. The company has already achieved independent product design and in-house production of core components, delivering affordable equipment for patients by addressing key clinical pain points. We are delighted to collaborate with Jizhi Medical, a team characterized by sustained creativity and efficient execution, supporting its continuous innovation and advancement in the fields of rehabilitation robotics and digital fitness. We expect and believe that Jizhi Medical will become a leading international enterprise in the intelligent health sector, renowned for its exceptional value, providing higher-value products and services to customers, and spearheading industry transformation and change.”

QianDao Group Investorstated: “As a comprehensive investment holding conglomerate, the Group considers biopharmaceuticals and medical technology to be key investment sectors. Leveraging over a decade of experience in interpreting overseas clinical rehabilitation research data, the Jizhi Medical team possesses a strong background in the integration of medicine and engineering. The team has a profound understanding of pain points in clinical rehabilitation and demonstrates industry-leading capabilities in product development and clinical implementation. Beyond strategic product placement from an application perspective, the team has made significant accumulations in core technologies. We are optimistic that the Jizhi Medical team’s international vision will bring greater value and possibilities to the smart health sector.”

China Xinxing Asset Management Co., Ltd. was established in 1989 and underwent mixed-ownership reform in 2021. The company focuses on innovative enterprises in sectors such as high-end manufacturing, next-generation information technology, pharmaceuticals and healthcare, new energy, and new materials. It is committed to unlocking the potential of high-quality enterprises and fostering mutual growth with its portfolio companies. As a central state-owned enterprise that has implemented mixed-ownership reform, China Xinxing Asset Management Co., Ltd. will uphold its mission of “serving national strategies and supporting emerging industries,” continue to leverage capital empowerment, and actively build an industrial investment and asset management platform characterized by innovative development concepts and dedicated to serving national strategies.

Qiandao Group was founded in 2011. Upholding the philosophy of “empowering finance with technology, serving industries through financial services, and contributing to the nation through industrial development,” the Group has deeply participated in China’s economic growth and industrial upgrading, striving to become a comprehensive holding group led by technological innovation and dedicated to serving the real economy. Its subsidiaries include Qiandao Investment Fund Management Co., Ltd., which focuses on pharmaceuticals, medical technology, advanced manufacturing, and new energy, as well as China Xinxing Asset Management Co., Ltd., a mixed-ownership subsidiary of a central state-owned enterprise, among other member companies. The Group specializes in asset management and investment activities such as equity investment, industrial investment, and special opportunity investment. Aligning closely with national policy directions, Qiandao Group strategically positions itself in strategic emerging industries designated by the state. It remains steadfast in leveraging technological innovation to support the growth of numerous “Specialized, Refined, Differential, and Innovative” (SRDI) enterprises. Based on in-depth research and cultivation of focused industries, the Group empowers industrial upgrading by engaging deeply across upstream and downstream segments of the industrial chain through professional capital operations and resource integration, bringing enduring vitality and promise to industrial development.